New oral anticoagulants in the management of venous thromboembolism: A major advance?

European Journal of Vascular and Endovascular Surgery

Volumn 48, Issue 5, 2014, Pages 487-488

  Sciascia, S ^a,b   Hunt, B J ^a,c  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF TURIN   (Italy)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; EDOXABAN; FONDAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; WARFARIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; THIAZOLE DERIVATIVE; THIOPHENE DERIVATIVE;

ANTICOAGULATION; BLEEDING; BRAIN HEMORRHAGE; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HEMOSTASIS; HUMAN; RISK REDUCTION; VENOUS THROMBOEMBOLISM; ANALOGS AND DERIVATIVES; SECONDARY PREVENTION;

ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; HUMANS; MORPHOLINES; PYRAZOLES; PYRIDINES; PYRIDONES; SECONDARY PREVENTION; THIAZOLES; THIOPHENES; VENOUS THROMBOEMBOLISM;

EID: 84908347488     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1016/j.ejvs.2014.07.007     Document Type: Editorial

References (11)

1. J. Bigby, J. Dunn, L. Goldman, J.B. Adams, P. Jen, and C.S. Landefeld Assessing the preventability of emergency hospital admissions. A method for evaluating the quality of medical care in a primary care facility Am J Med 83 1987 1031 1036
2. M. Pirmohamed, and B.K. Park Adverse drug reactions: back to the future Br J Clin Pharmacol 55 2003 486 492
3. K.A. Breen, and B.J. Hunt The new oral anticoagulants Clin Med 11 2011 467
4. http://www.nice.org.uk/guidance/CG144. Retrieved July 16, 2014.
5. http://publications.nice.org.uk/rivaroxaban-for-treating-pulmonary-embolism-and-preventing-recurrent-venous-thromboembolism-ta287/sources-of-evidence-considered-by-the-committee. Retrieved July 16, 2014.
6. P. Lefebvre, C.I. Coleman, B.K. Bookhart, S.T. Wang, S.H. Mody, and K.N. Tran Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism J Med Econ 17 2014 52 64
7. C.D. Seaman, K.J. Smith, and M.V. Ragni Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: a U.S. perspective Thromb Res 132 2013 647 651
8. D. Dowlatshahi, K.S. Butcher, N. Asdaghi, S. Nahirniak, M.L. Bernbaum, A. Giulivi Canadian PCC Registry (CanPro) Investigators Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal Stroke 43 2012 1812 1817
9. J. van Ryn, J. Stangier, S. Haertter, K.H. Liesenfeld, W. Wienen, and M. Feuring Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity Thromb Haemost 103 2010 1116 1127
10. J. Stangier, K. Rathgen, H. Stahle, and D. Mazur Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study Clin Pharmacokinet 49 2010 259 268
11. E.S. Eerenberg, P.W. Kamphuisen, M.K. Sijpkens, J.C. Meijers, H.R. Buller, and M. Levi Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects Circulation 124 2011 1573 1579